Update on Pediatric and Young Adult Mature Lymphomas

Emily F Mason; Alexandra E Kovach

doi:10.1016/j.cll.2021.03.018

Update on Pediatric and Young Adult Mature Lymphomas

Clin Lab Med. 2021 Sep;41(3):359-387. doi: 10.1016/j.cll.2021.03.018. Epub 2021 Jul 1.

Authors

Emily F Mason¹, Alexandra E Kovach²

Affiliations

¹ Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, 4603A TVC, Nashville, TN 37232-5310, USA. Electronic address: emily.f.mason@vumc.org.
² Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, 4650 Sunset Boulevard, Mailstop #32, Los Angeles, CA 90027, USA.

PMID: 34304770
DOI: 10.1016/j.cll.2021.03.018

Abstract

After acute leukemia and brain and central nervous system tumors, mature lymphomas represent the third most common cancer in pediatric patients. Non-Hodgkin lymphoma accounts for approximately 60% of lymphoma diagnoses in children, with the remainder representing Hodgkin lymphoma. Among non-Hodgkin lymphomas in pediatric patients, aggressive lymphomas, such as Burkitt lymphoma, diffuse large B-cell lymphoma, and anaplastic large cell lymphoma, predominate. This article summarizes the epidemiologic, histopathologic, and molecular features of selected mature systemic B-cell and T-cell lymphomas encountered in this age group.

Keywords: ALK positive; Aggressive B-cell lymphoma; Anaplastic large cell lymphoma; Hodgkin lymphoma; IRF4; Pediatric mature lymphoma; Pediatric type.

Publication types

Review

MeSH terms

Child
Humans
Lymphoma, Large B-Cell, Diffuse*
Lymphoma, T-Cell*
Young Adult